Unusual early-stage pancreatic sarcomatoid carcinoma

Table 1 Pretreatment serum tumor markers

Tumor markers	Index	Normal range
CA19-9 (KU/L)	1.21	< 35.00
CA242 (KU/L)	1.14	< 20.00
CA125 (KU/L)	11.71	< 35.00
CA15-3 (KU/L)	2.32	< 35.00
NSE (ng/mL)	23.42	< 13.00
CEA (ng/mL)	0.24	5
Ferritin (ng/mL)	161.47	< 322.00
β-HCG (MIU/mL)	0.12	< 3.00
AFP (ng/mL)	1.07	< 20.00
Free-PSA (ng/mL)	0.32	< 1.00
PSA (ng/mL)	1.53	< 5.00
HGH (ng/mL)	0.36	< 7.50

CA: Cancer antigen; NSE: Neuron-specific enolase; CEA: Carcinoembryonic antigen; β-HCG: β-human chorionic gonadotropin; AFP: α-fetoprotein; PSA: Prostate-specific antigen; HGH: Human growth hormone.

Table 2 Plasma transforming growth factorβ1 and interleukin-11 in sarcomatoid carcinoma before any treatment

	Tumor (pg/mL)	Index (median)	n
TGFβ1	SCP	35688	1
	PDAC	10475 (5142-30865)	20
	PanINs	7949 (6655-11404)	10
	HC	6865 (3272-22463)	11
IL-11	SCP	58	1
	HC	22 (10-42)	11

SCP: Sarcomatoid carcinoma of the pancreas; HC: Healthy control; PDAC: Pancreatic ductal adenocarcinoma; PanINs: Pancreatic intraepithelial neoplasias; TGF: Transforming growth factor; IL-11: Interleukin-11.